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Abstract
Background: BK-UM (CRM197) is a mutant form of diphtheria toxin and a specific inhibitor of heparin-binding
epidermal growth factor-like growth factor (HB-EGF). We assessed the safety, pharmacokinetics, recommended
dose, and efficacy of BK-UM in patients with recurrent ovarian cancer (OC) or peritoneal cancer (PC), and measured
HB-EGF levels in serum and abdominal fluid after BK-UM administration.
Methods: Eleven patients with advanced or recurrent OC or PC were enrolled and treated with BK-UM via the
intraperitoneal route. The dose was escalated (1.0, 2.0, 3.3, and 5.0 mg/m2) using a 3 + 3 design.
Results: Eight of 11 patients completed treatment. No dose-limiting toxicity (DLT) was experienced at dose levels 1
(1.0 mg/m2) and 2 (2.0 mg/m2). Grade 3 transient hypotension as an adverse event (defined as a DLT in the present
study) was observed in two of four patients at dose level 3 (3.3 mg/m2). Treatment with BK-UM was associated with
decreases in HB-EGF levels in serum and abdominal fluid in seven of 11 patients and five of eight patients,
respectively. Clinical outcomes included a partial response in one patient, stable disease in five patients, and
progressive disease in five patients.
Conclusions: BK-UM was well tolerated at doses of 1.0 and 2.0 mg/m2, with evidence for clinical efficacy in
patients with recurrent OC or PC. A dose of 2.0 mg/m2 BK-UM is recommended for subsequent clinical trials.
Trial registration: This trial was prospectively performed as an investigator-initiated clinical trial. The trial numbers
are UMIN000001002 and UMIN000001001, with registration dates of 1/30/2008 and 2/4/2008, respectively.
UMIN000001001 was registered as a trial for the continuous administration of BK-UM after UMIN000001002.
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Background
Ovarian cancer (OC) is a lethal gynecologic malignancy
that has an extremely poor prognosis, due to the exten-
sion of OC cells into the peritoneal cavity [1]. Metastasis
from epithelial ovarian cancer (EOC) can occur via
hematogenous, lymphatic, or transcoelomic routes, of
which the last is the most common, and is responsible
for the highest prevalence of morbidity and mortality in
patients with OC [1]. Most patients with recurrent OC
experience massive ascites and ileus associated with
transcoelomic metastasis, and preventing transcoelomic
metastasis may thus play a key role in improving the
prognosis in OC patients.
In the past decade, cytoreductive surgery and the
introduction of platinum plus taxane-based chemother-
apies have improved survival in patients with EOC [2,
3]. In the International Collaborative Ovarian Neoplasm
7 trial, standard chemotherapy with bevacizumab failed
to increase overall survival in patients with newly diag-
nosed OC, but did improve progression-free survival
and retention of peritoneal fluid [4]. Platinum is recog-
nized as a key drug for OC therapy [5], and the develop-
ment of biological agents and molecular-targeted
therapeutics with low toxicity are needed to overcome
resistance or restore sensitivity to platinum.
Heparin-binding epidermal growth factor-like growth
factor (HB-EGF) is an epidermal growth factor receptor
(EGFR) ligand [6]. HB-EGF is initially synthesized as a
transmembrane protein (proHB-EGF), which is then
cleaved by a protease at the cell surface to yield the
mitogenic-active soluble form of HB-EGF (sHB-EGF)
via ectodomain shedding [7]. sHB-EGF is a potent mito-
gen that promotes cell adhesion, cell motility, and angio-
genesis [8]. HB-EGF also contributes to resistance to
chemotherapy [9]. HB-EGF expression was shown to be
enhanced in cancer tissues or peritoneal tissues in OC
patients [10–13], and high expression of HB-EGF in can-
cer tissues was significantly associated with a poor prog-
nosis in OC [10]. Emerging evidence suggests that HB-
EGF is a rational therapeutic target for cancers, includ-
ing OC, gastric cancer, and breast cancer [14, 15].
CRM197 is the active ingredient of the investigational
drug BK-UM. CRM197 was originally isolated as a non-
toxic mutant form of diphtheria toxin (DT), and has
since been shown to inhibit the proliferation of cancer
cells by three modes of action [16–18]. CRM197
strongly inhibited tumor growth in nude mice in various
cell systems [10]. However, CRM197 displays 106-fold
less toxicity than DT [17], which is recognized as being
extremely toxic, Massive release of DT is likely to cause
lethal necrosis in the heart and liver, with a reported le-
thal dose in humans of about 0.1 μg/kg body weight
[19]. It is therefore necessary to monitor any potential
severe adverse effects of BK-UM, including cardio-,
neuro-, or nephrotoxicities, irrespective of its route of
administration.
CRM197 was safe and relatively well tolerated when
injected subcutaneously via the abdominal wall on alter-
nate days for 6 days at 1.7, 2.6, and 3.5 mg/day in pa-
tients with recurrent cancer [20]. In a pre-clinical study,
we reported that daily intraperitoneal administration of
BK-UM, which has demonstrated a potentially dose-
dependent anti-cancer effect, may be the optimal regi-
men [21]. Herein, we report the results of a phase-I
study designed to assess the safety, pharmacokinetics,
recommended phase-II dose, and efficacy of BK-UM in
patients with recurrent OC or peritoneal cancer (PC).
Methods
Patient selection
This clinical trial was undertaken as an open-label,
phase-I dose-escalation study, and was performed as a
prospective investigator-initiated clinical trial. The study
was conducted at Fukuoka University Hospital (Fuku-
oka, Japan) in accordance with the principles of the Dec-
laration of Helsinki and the International Conference on
Harmonization’s Good Clinical Practice Guidelines. The
study protocol was approved by the Institutional Review
Board of Fukuoka University Hospital.
Study-inclusion criteria were:(i) EOC or primary PC
confirmed by histology; (ii) recurrent OC or PC within
6 months after completion of a primary treatment con-
taining platinum and a taxane (including patients who
had received second- or subsequent-line chemotherapy
after recurrence following primary treatment containing
platinum and a taxane); (iii) performance status 0 or 1
according to the Eastern Cooperative Oncology Group
classification; (iv) evidence of adequate liver, kidney, and
bone marrow functions (absolute white blood cell count
>3000/μL, or neutrophil count ≥1000/μL, platelet count
≥100,000/μL, hemoglobin ≥8.0 g/dL, aspartate amino-
transferase ≤2.5-fold the upper limit of normal, alanine
transaminase ≤2.5-fold the upper limit of normal, serum
total bilirubin ≤1.5 mg/dL, serum creatinine ≤1.5 mg/
mL); (v) detectable levels of HB-EGF in serum or peri-
toneal fluid; (vi) diphtheria antibody titer <0.1 IU/mL;
and (vii) practicality of placing a port in the abdomen.
All subjects underwent electrocardiography to confirm
the absence of abnormalities requiring treatment, and
sensory and motor nerve-conduction studies to evaluate
peripheral neuropathy.
Exclusion criteria were: (i) history of cardiac disease ≥
III according to the New York State Heart Association
classification; (ii) <50% left ventricular ejection fraction
by echocardiography; (iii) myocardial infarction within
6 months of study enrollment; (iv) uncompensated liver
cirrhosis; (v) severe lung disease necessitating oxygen in-
halation; (vi) psychotic disorders; (vii) uncontrolled
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diabetes mellitus; (viii) ileus or subileus; (ix) uncon-
trolled infectious disease; (x) peripheral neuropathy of
grade ≥2; (xi) pregnancy or breastfeeding; (xii) life ex-
pectancy <3 months; (xiii) receipt of an investigational
agent within 28 days before study enrollment; and (xiv)
history of administration of antiserum.
Concurrent investigational or antineoplastic agents
were not permitted during the study.
Investigational drug
CRM197 was produced from Corynebacterium diph-
theria C7β (197) and purified by the Kanonji Institute at
the Research Foundation for Microbial Diseases of
Osaka University (Osaka, Japan). BK-UM contained
CRM197, sodium phosphate, and sucrose. BK-UM was
also produced at the above institute according to good
manufacturing practice.
Study design
This was a dose-escalation study with a 3 + 3 trial design
at each dose to determine the maximum-tolerated dose
(MTD) and recommended dose. BK-UM was adminis-
tered intraperitoneally at doses of 1.0, 2.0, 3.3, and
5.0 mg/m2, 5 days a week for 2 weeks, based on the re-
sults of a pre-clinical study [21]. An anti-histamine was
administered as premedication before BK-UM injection.
Dose escalation of BK-UM was investigated by the Data
and Safety Monitoring Committee (DSMC). Treatment
of the first patient was finished completely, and the
safety of BK-UM was then reviewed by the DSMC. If no
dose-limiting toxicity (DLT) was observed in three pa-
tients at a given dose, the next three patients were
treated with the next-higher dose. If DLT was experi-
enced by one or two of the three patients at any dose,
three additional patients were treated with the same
dose. If two or fewer of six patients treated with a given
dose exhibited DLT, this dose was considered to exceed
the MTD and dose escalation was halted. The recom-
mended phase-II dose was defined as one dose level
lower than the MTD. Patients who progressed after
showing a response to BK-UM were not allowed to be
re-treated with BK-UM. If more than two patients with-
drew from the present study, safety was evaluated by the
DSMC. Conventional chemotherapy was administered in
patients who requested it after the observation period of
the trial, for as long as there was a diagnosis of progres-
sive disease, or for six courses in patients with stable dis-
ease (SD), partial response (PR), or complete response.
Safety evaluation and definition of DLT
Safety was evaluated every week during treatment and
until 6 weeks after the first infusion of BK-UM. Safety of
BK-UM was evaluated according to adverse events (AEs)
detected via vital signs, physical signs, whole blood cell
counts, serum chemistry, urinalyses, 12-lead electrocar-
diography, cardiac monitoring, echocardiography,
muscle tests, neural reflex tests, nerve conduction vel-
ocity testing, and thoracoabdominal radiographs. La-
boratory tests for in cardiotoxicity were also undertaken.
All AEs were graded according to the Common Ter-
minology Criteria for Adverse Events v3.0 set by the Na-
tional Cancer Institute. DLT was defined as an AE or
laboratory abnormality that occurred 6 weeks after the
first infusion of BK-UM. A DLT was judged to be related
to BK-UM if it met any of the following criteria:
hematologic toxicity grade ≥4; gastrointestinal disorder
possibly due to peritonitis carcinomatosa grade ≥4; or
non-hematologic toxicity grade ≥3. Safety data were
evaluated by the DSMC at all doses.
Efficacy assessments
Responses were evaluated 6 weeks after the first infusion
of BK-UM. Recurrent lesions were evaluated by com-
puted tomography before infusion of BK-UM, to provide
baseline images. Clinical evaluation of response was esti-
mated using baseline computed tomography images and
findings 6 weeks after the first infusion of BK-UM, ac-
cording to Response Evaluation Criteria in Solid Tumors
(RECIST) v1.0 guidelines. The interval for overall sur-
vival was defined as the period from the day of the first
infusion of BK-UM to the day on which death occurred.
Some patients were discharged from Fukuoka University
Hospital after the end of this clinical trial and treated at
other hospitals, and the dates of death for these patients
were recorded using information acquired from those
hospitals.
Pharmacokinetics
Blood samples were collected before and at 1, 3, 6, and
12 h after infusion of each dose on day 1. Pre-dose sam-
ples were collected on days 2–5 and 8–12. Samples were
collected in a heparinized tube and centrifuged at
3000 × g for 10 min at room temperature. Plasma sam-
ples were stored at −80 °C for analysis of BK-UM con-
centrations. Plasma concentrations of BK-UM were
determined by enzyme-linked immunosorbent assay
(ELISA). Plates were coated with an anti-DT monoclonal
antibody to capture CRM197, followed by the addition
of diluted plasma samples obtained from patients, and a
horseradish peroxidase-labeled monoclonal antibody
against DT. The sensitivity of this assay was ≥20 ng/mL.
Measurement of HB-EGF levels in serum and abdominal
fluid
Blood and abdominal fluid were withdrawn from all pa-
tients into anticoagulant-excluded tubes before and after
infusion of BK-UM. HB-EGF concentrations in serum
and abdominal fluid were determined by a modified
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enzyme assay [22] using a sandwich ELISA (DuoSet;
R&D Systems, Minneapolis, MN, USA).
Results
Patient characteristics
This trial was conducted at 12/10/2007. Eleven of 50 pa-
tients with recurrent cancer were enrolled, including 10
with OC and one with primary PC (Table 1). The
remaining 39 patients were not eligible for the following
reasons: 12 patients had diphtheria antibody levels
>0.1 IU/mL; 21 and five patients had performance sta-
tuses of 2 or 3, respectively; and one patient recurred
more than 6 months after primary treatment containing
platinum and a taxane. Among the patients who re-
ceived BK-UM at 1.0 mg/m2 (level 1 dose), one patient
had leptomeningeal disease previously treated using a γ-
knife, but had been in a stable condition for 4 months.
Four patients (numbers 1–4) were enrolled at 1.0 mg/m2
BK-UM (dose level 1) because one patient who lived in
Tokyo wanted to return to Tokyo, and withdrew their
consent soon after BK-UM treatment.
Eight patients completed the study according to the
protocol, one patient withdrew their consent as noted
above, and two patients dropped out of the trial because
of DLTs. All 11 enrolled patients were evaluated for
safety and efficacy on an intent-to-treat basis.
Safety and tolerability
All AEs of grade ≥2 are listed in Table 2. All patients ex-
perienced at least one AE. At BK-UM doses of 1.0 and
2.0 mg/m2 (dose levels 1 and 2), all AEs were considered
unlikely to have a causal association with BK-UM. Grade
3 AEs such as ileus, abdominal fullness, and anemia
were observed in one patient at 2.0 mg/m2 BK-UM (dose level 2). Most patients had grade 1 fever between
days 1 and 3 of BK-UM treatment, but neither the fre-
quency nor severity of these AEs increased with dose es-
calation. BK-UM was thus generally considered to be
well-tolerated at doses of 1.0 and 2.0 mg/m2. However,
both patients treated at 3.0 mg/m2 BK-UM (dose level 3)
developed grade 3 hypotension on day 8 of treatment,
which was defined as a DLT. This AE manifested as nau-
sea, abdominal pain, and transient hypotension, accom-
panied by irritation of the peritoneum, fever, and
elevated C-reactive protein levels. Complete recovery
from all AEs was observed within 1 week in both pa-
tients. All other AEs observed at dose level 3 were grade
≤2. No severe AEs (grades 4 or 5), including severe car-
diotoxicity- or neurotoxicity-related DLTs, were found in
any patient at any dose level.
Dose escalation and MTD
No DLT was observed at dose levels 1 and 2, but two
patients at dose level 3 showed grade 3 hypotension
8 days after the first infusion. The MTD was therefore










1 OVCA (EMC) 5 lines None 1
2 OVCA (SCC) 2 lines None 1
3 OVCA (SCC) 2 lines None 1
4 OVCA (SCC) 1 lines γ-knife 1
5 PC (SCC) 2 lines None 1
6 OVCA (SCC) 3 lines None 1
7 OVCA (SCC) 8 lines None 0
8 OVCA (SCC) 7 lines None 1
9 OVCA (SCC) 4 lines None 1
10 OVCA (CCC) 5 lines None 1
11 OVCA (TCC) 4 lines None 0
Age-range of the patients is 46 to 70 years
OVCA ovarian cancer, EMC endometrioid adenocarcinoma, SCC serous
cystadenocarcinoma, PC peritoneal cancer, CCC clear cell carcinoma, TCC
transitional cell carcinoma, PS performance status
Table 2 Adverse events by grade in this phase-I study
Level 1 Level 2 Level 3
Patient no. 1 2 3 4 5 6 7 8 9 10 11





Constipation 2 2 2
Diarrhea 2
Abdominal pain 2 2








Anemia 2 2 2 3 2
Elevation of ALT 2
Elevation of CRP 2 2c 2c
Hypoalbuminemia 2 2
Hypotensionb 3c 3c
aHematoma in the inserted port
bTransient hypotension accompanied by abdominal peritoneal irritation
cAdverse events during the administration of BK-UM
No asterisk in adverse events indicates events monitored during the
observation period after the administration of BK-UM
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judged to be at dose level 3 (3.0 mg/m2), and the recom-
mended dose was determined to be 2.0 mg/m2.
Pharmacokinetics
The plasma concentration of BK-UM after intraperito-
neal administration was measured 15 times per course
in each patient. At 1.0 mg/m2 BK-UM (dose level 1),
plasma BK-UM was only detected in three of 60 samples
from four patients. BK-UM plasma levels were detected
in nine of 45 samples from three patients at 2.0 mg/m2
(level 2) and 11 of 51 samples from four patients at
3.0 mg/m2 (level 3). The plasma concentration of BK-
UM was unmeasurable throughout the treatment with
BK-UM in five patients, while BK-UM was only sporad-
ically detected in plasma in the remaining six patients.
These results suggested that intraperitoneal delivery of
BK-UM did not result in clinically relevant plasma ex-
posure (Additional file 1: Table S1).
Evaluation of response
BK-UM treatment resulted in reductions in HB-EGF
serum concentrations in five patients, in abdominal fluid
in four patients, and in abdominal fluid and serum in
four patients (Table 3). Patients 2, 8, and 11 were not in-
cluded in this analysis because HB-EGF concentrations
were not measured on the scheduled day after BK-UM
treatment in these patients. The present results sug-
gested that BK-UM reduced HB-EGF concentrations in
abdominal fluid or serum if the HB-EGF concentration
was ≥125 pg/mL. Serum levels of cancer antigen-125
also decreased in two of 11 patients. DT antibody levels
were increased in all patients after BK-UM treatment.
One of the 11 patients achieved PR (Table 3), five pa-
tients showed SD, and the remaining five patients
showed progressive disease. In addition to the abdominal
cavity, patients 4, 6, and 9 had metastatic lesions in the
brain, liver, and lungs, respectively (though patient num-
ber 4 had a history of leptomeningeal disease previously
treated by γ-knife, and had been in a stable condition for
4 months). The metastatic lesions in the abdominal cav-
ity in these three patients were markedly reduced after
BK-UM treatment, even though the extra-abdominal le-
sions had progressed or were stable. At least three pa-
tients received intraperitoneal administration of BK-UM
1 mg/m2 or 2 mg/m2 for 2 weeks. Only patients 1 and 4
(level 1) received two courses of intraperitoneal BK-UM
(1 mg/m2), and responses in these patients were evalu-
ated at week 8 after the start of the first course of BK-
UM, compared with evaluation at week 6 in the other
patients who only received one course of intraperitoneal
BK-UM. The benefit of intraperitoneal administration of
BK-UM thus lasted up to 6 weeks in patients 3, 5, 10,
and 11, and 8 weeks in patients 1 and 4. Conventional
chemotherapy was started at week 9 in patients 1 and 4,
and week 7 in patients 3, 7, 8, 10, and 11. Patients 2,
5, 6, and 9 requested no further therapy. Five of the
seven patients who received further conventional
chemotherapy exhibited overall survival beyond
14 months (Table 4). Three patients (1, 3, and 11)
showed no evidence of disease following BK-UM
treatment and subsequent therapy, and one patient
(11) remained free of disease.
Discussion
HB-EGF is a ligand that binds to the EGFR. Although
several studies have investigated anti-cancer agents
targeting the EGFR and other ERBB family receptors,
few clinical trials have investigated the use of agents
targeting EGF family growth factor ligands [23]. Previ-
ous studies have suggested that HB-EGF is expressed
Table 3 Clinical effects in this phase I study
Patient
no.
HB-EGF in serum (pg/mL) HB-EGF in abdominal fluid (pg/mL) Serum CA125 (IU/mL) Anti-diphtheria toxin antibodies (IU/mL) Efficacy
Pre-Tx Post-Tx Pre-Tx Post-Tx Pre-Tx Post-Tx Pre-Tx Post-Tx
1 1971 196 2169 106 291 137 <0.01 2.56 SD
2 556 349a 416 560a 1411 3487 <0.01 124 PD
3 297 172 593 292 46 50 <0.01 >131 SD
4 267 85 143 34 1408 2217 0.04 >131 PR
5 51 101 55 399 267 600 0.03 31.1 SD
6 74 109 109 171 254 158 <0.01 81.9 PD
7 67 79 130 ND 2813 3983 <0.01 0.06 PD
8 162 141a 140 132a 3894 5147 0.13 20.5 PD
9 231 130 237 66 1856 3984 0.01 1.02 PD
10 247 140 ND ND 40 63 <0.01 >41.0 SD
11 67 155a ND ND 16 94 <0.01 >6.56 SD
Pre-A pre-administration of BK-UM, Post-A post-administration of BK-UM, ND not determined, SD stable disease, PD progressive disease, PR partial response
aHB-EGF level was measured on the final day of investigation
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at high levels in OC patients, and represents a prom-
ising target for OC treatment [10, 14]. However, the
current study provides the first evidence of HB-EGF
values in OC patients.
A previous phase-I study of intraoperative intraperitoneal
administration of 60–100 mg/m2 cisplatin detected a max-
imum plasma concentration of cisplatin of 0.7–2.3 μg/mL
after 1–1.5 h, giving a mean peritoneal-to-plasma area-
under-the-curve ratio during perfusion of 19.5 for 100 mg/
m2 [24]. The plasma cisplatin level ranged from one-third
to one-tenth of the total amount of intraperitoneally ad-
ministered cisplatin. Conversely, the plasma BK-UM level
was >20 ng/mL. Intraperitoneal administration of 1–
3.3 mg/m2 BK-UM would be expected to result in plasma
levels of ≥100 ng/mL; however, BK-UM was undetectable
in most plasma samples in the current study. There are sev-
eral possible reasons for this phenomenon: (i) BK-UM may
not pass through peritoneal membranes readily because of
its high molecular weight; (ii) BK-UM may be absorbed
readily into the lymphatic system in the peritoneum; and
(iii) most BK-UM may bind rapidly to the peritoneum, with
high expression of HB-EGF on peritoneal membranes. In
the present study, even patients with DLTs had undetect-
able plasma levels of BK-UM, suggesting that AEs are in-
duced by local administration of BK-UM.
Hypersensitivity was mitigated by administration of an
anti-histamine in all patients before intraperitoneal ad-
ministration of BK-UM. Although fever (a common AE)
occurred up to 3 days after the beginning of BK-UM ad-
ministration, it was not accompanied by general fatigue,
suggesting that the fever was generated locally. Other
AEs, including nausea, vomiting, appetite loss, and ab-
dominal fullness, could have been related to recurrent
disease. Two patients treated at dose level 3 developed
transient hypotension as a DLT at day 8, associated with
uncontrolled abdominal pain and elevated C-reactive
protein levels. Two patients with DLTs at dose level 3
did not have ascites, whereas the other two patients who
did have ascites had no severe AEs. Transient
hypotension could have been mediated by a parasympa-
thetic reaction related to stimulation of the peritoneum
by BK-UM, which could have caused inflammation in
the abdominal cavity. It was also notable that both pa-
tients developed DLT hypotension at day 8. BK-UM sup-
presses the function of HB-EGF in the peritoneum,
suggesting that it may be associated with blocking the
circulation of peritoneal fluid, and high concentrations
of BK-UM may thus cause excessive peritoneal stimula-
tion. In a phase-I study of a monoclonal antibody
(KHK2866) against HB-EGF, neurotoxicity manifested as
complex partial seizures, aphasia, and confusion after
first-dose intravenous administration, but these AEs
were reversible and unpredictable [23, 25]. In the
present study, muscle tests, neural reflex tests, and nerve
conduction velocity tests revealed no neurotoxic abnor-
malities in any patient. However, in the event of intra-
venous administration of BK-UM, patients should be
closely monitored for severe AEs such as cardiotoxicity,
neurotoxicity, and nephrotoxicity.
The present study enrolled patients who had progressed
to advanced disease despite previous treatments with sev-
eral chemotherapeutic regimens. In addition, safety evalu-
ations were performed 8 weeks after enrollment in
patients who received one cycle of the present study treat-
ment. Chemotherapeutic regimens are usually repeated
for 3–4 weeks in OC patients, and demonstrating clinic-
ally favorable efficacy of BK-UM would thus be difficult
because of the long observation period in the current
study. However, one of five patients achieved PR or SD,
suggesting that BK-UM may be effective against peritoneal
dissemination of OC. Seven of 11 patients were treated
with conventional chemotherapy after intraperitoneal ad-
ministration of BK-UM, five of whom survived for
>14 months. These five patients also had PR or SD, and
four of them received another platinum-based chemo-
therapeutic regimen. In principle, the prognosis of
OC depends on the tumor’s sensitivity to platinum
[5], and patients who are refractory or resistant to
platinum treatment showed a sensitivity of <10% to
second-line chemotherapy [5]. These results suggest
that BK-UM may represent a promising anti-cancer
agent for OC therapy, by rescuing platinum sensitivity
by improving peritoneal dissemination. Conversely,
intrahepatic lesions or pleural effusions were exacer-
bated by intraperitoneal administration of BK-UM,
though it is possible that replacing local intraperito-
neal therapy with systemic intravenous administration
of BK-UM could improve intrahepatic lesions or
pleural effusions.







1 CDDP + CPT-11 (6 courses) 28.1
2 – 3.4
3 CDDP + CPT-11 (6 courses) 24.3
4 CDDP + CPT-11 (6 courses) 15.1
5 – 5.5
6 – 5.0
7 CDDP + CPT-11 (2 courses) 7.4
8 CDDP + IFM (2 courses) 4.2
9 – 3.6
10 CPT-11 (6 courses) 14.0
11 CBDCA + Doxil (6 courses) >60a
CDDP cisplatin, CPT-11 irinotecan, IFM Ifosfamide, CBDCA carboplatin, Doxil
doxorubicin hydrochloride liposome injection
aPatient alive at 11/1/2016
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HB-EGF levels in serum have been shown to be correlated
with levels in abdominal fluid and cancer tissues in OC pa-
tients [22]. However, HB-EGF is cleaved by a disintegrin and
metalloproteinase (ADAM) and other membrane proteases,
including membrane-type 1 matrix metalloprotease (MT1-
MMP) [26]. However, the form of HB-EGF measured by
ELISA in the current study was only cleaved by ADAM
(preliminary results), while the form of HB-EGF cleaved by
ADAM and MT-MMPs can be blocked by BK-UM [26]. In
our study, BK-UM treatment elicited SD in some patients
with low HB-EGF levels. Levels of the active form of HB-
EGF might be elevated in patients with recurrent OC. The
development of a kit for measuring all forms of HB-EGF is
needed to facilitate further studies of BK-UM.
Conclusion
The results of this first-in-human study demonstrated that
BK-UM is safe and well tolerated for the treatment of OC,
with an MTD and recommended dose for phase-II studies
of 3.3 mg/m2 and 2.0 mg/m2, respectively. Further investi-
gations should focus on the: (i) route of administration of
BK-UM; (ii) the development of a kit for measuring asso-
ciated targeted molecules; and (iii) the combination of
conventional anti-cancer agents with BK-UM.
Additional file
Additional file 1: Table S1. Pharmacokinetics of BK-UM. (PDF 48 kb)
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